XmAb23104 (PD1 X ICOS) and XmAb22841 (CTLA-4 X LAG3) in Treating Melanoma Prior Immune Checkpoint Inhibitor Therapy
Summary
This is a first-in-human, multi-center, multi-cohort, open-label, phase Ib/II study of XmAb22841 (CTLA-4 X LAG3) administered in combination with XmAb23104 (PD1 X ICOS) in participants with a histologically or cytologically confirmed diagnosis of an advanced/metastatic melanoma. XmAb22841 (CTLA-4 X LAG3) is a bi-specific antibody targeting two different T cell membrane proteins responsible for regulation of T cell activity. It offers potential immunologic and safety advantages over existing therapies. XmAb22841 (CTLA-4 X LAG3) is being evaluated in this clinical study designed to assess the safety, tolerability, PK, and PD of escalating doses of XmAb22841 (CTLA-4 X LAG3) administered in combination with XmAb23104 (PD1 X ICOS) The study will be conducted through the University of California Melanoma Consortium (UCMC).
Timeline
- Start
- 2023-02-28
- Primary completion
- 2024-04-29
- Completion
- 2024-04-29
Outcome
Outcome not reported
Stopped (Business): “Sponsor decision”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BAVUNALIMAB | Monoclonal antibody | 0.3 mg/kg | Intravenous |
| Subject | BAVUNALIMAB | Monoclonal antibody | 1 mg/kg | Intravenous |
| Subject | BAVUNALIMAB | Monoclonal antibody | 3 mg/kg | Intravenous |
| Subject | IZURALIMAB | Monoclonal antibody | 10 mg/kg | Intravenous |